On the other hand, an increase of circulating levels of HMGB1 following anti-cancer treatments like neo-adjuvant chemotherapy or oncolytic virotherapy has been associated with anti-tumor response and partial remission, suggesting that circulating HMGB1 may be indicating the size of immunogenic cancer cell death (264, 287, 288). The gene discussed is HMGB1; the disease is neoplasm.